Biomarkers play a dynamic role in accepting the relationships between exposure to environmental chemicals, the development of chronic human diseases, and the identification of subgroups that are at increased risk for disease. Biomarker is the indicator that can be accurately measured as signal of normal biological functioning, pathogenic paths or a drug response to a therapeutic drug mediation. Biomarkers are usually in molecular form. Biomarkers take place in various body functions, including disease diagnosis and prognosis, prediction and calculation of treatment response, and safety estimation.
Biomarkers Conference Paris France will be covering diverse topics of Clinical Neuroscience such as Molecular Biomarkers, Biomarkers in Oncology, Biomarker Discovery &Validation, Biomarkers in Patient Selection, Biomarkers in Clinical Development & Clinical Trials, Biomarkers in Drug discovery and development, Biomarkers for Early Detection and Prognosis, Histological Biomarkers, Cytological Biomarkers, Neurological Biomarkers, Immunological Biomarkers, Cardiovascular Biomarkers, Imaging Biomarkers, Emerging Therapeutic Biomarkers, Regulatory and Reimbursement Issues in Biomarkers, Biomarkers in Personalized Medicine, Biomarkers for precision medicine and autoimmune disease, Biomarkers Validation and Next-Generation sequencing, Radiation Biomarkers, Lipids Panel Biomarkers, Comprehensive Metabolic Panel (CMP) Biomarkers, Biomarkers For Non-Cancerous Diseases, Biomarker Testing, Biomarkers Based On Epidemiological Investigations
Learning is a never-ending process. We at Hilaris Conferences, will provide a unique platform for the learners, researchers, policymakers, and innovators to network and share knowledge. Hilaris Conferences will act as a bridge between the Academia & Industry to fill the knowledge gap and inspire young minds through its unique learning opportunities. Hilaris Conference will offer a huge opportunity to share creative ideas and promote the collaborative research environment through its specially designed networking sessions for a challenging future. Hilaris Meetings will establish a strong base for researchers and learners in the journey of their lifelong quest for knowledge.
Hilaris Conferences is going to host International Conferences, Meetings, Workshops, Events, and Symposiums in the vast domains of Life Sciences, Clinical Science, Medical Science, Healthcare, Agriculture & Food, Pharmaceuticals, Environmental Sciences, and Applied Engineering etc. We welcome you to be a part of the Hilaris Conference and share your knowledge for a glorious future. We seek the support of all the stakeholders to fulfil our vision "Join us as a Lerner and proceed as a Leader".
Biomarkers 2019 will gather international participants in Paris, France. This platform will provide an opportunity for academic and industry researchers, clinicians, investors and innovators to contemplate and establish new insights and developments in the area of Biomarkers, molecular biology, Oncology, Personalized Medicine, Drug Discovery, Immunology areas.
Who Should Attend
Biomarkers 2019 Conference welcomes Industry Researchers, Chief Executive Officers, Directors, Chief Scientific Officers, Chief Medical Officers, Head of Regulatory Affairs, Chief Operating Officer, Head of Legal & Intellectual Property, Research Heads, Consultants, Business Development & Sales Teams, Policymakers, Investors, Government Officials and other participants from: Biomarkers Research Center, Biomarkers Research Companies, Universities and many pharma companies are using Biomarkers research studies for drug/therapy developments are from the field of Oncology, Neurology, Immunology, Cardiovascular, Neurodegenerative disease, Cytology and also in diabetes for a better cure.
Target Audience:
From Academic Field-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
- Biomarkers Societies & Association’s persons
|
|
|
|
|
From Business/Industry Field-
|
|
|
|
|
|
|
|
|
|
- Advertising and Promotion Agency Executives
|
- Any person from Industrial Background
|
Middle East and Africa Biomarkers Market is expected to reach USD 6.92 billion by 2023 from USD 3.4 billion in 2018 growing at a CAGR of 15.29% during forecast period 2018-2023. The key players in biomarkers market include, Bio-Rad Labrotories(U.S.), Qiagen N.V.(Netherlands), Enzo Biochem (U.S.), PerkinElmer, Inc. (U.S.), Merck& Co, Inc.(U.S.), EKF Diagnostics Holdings pic.(U.S.), Meso Scale Diagnostics, LLC(U.S.), Singulex, Inc(U.S.), BioSims Technologies(France), Cisbio Bioassays( France), and Signosis, Inc(U.S.).
Cancer biomarkers market in the MEA is anticipated to witness lucrative growth over the forecast period due to the rising prevalence of cancer, improper diet, growing consumption of tobacco, lack of physical activities and frequent sun & UV exposure. Furthermore, increasing geriatric population base, growing awareness concerning the usage of biomarkers at various stages of cancers and increasing demand for clinical diagnosis in the early stage of cancers are some factors that are anticipated to boost usage rates. The high cost of diagnostic procedure is restraining the market growth.
The rising incidences of cancer, beginning research on cancer biomarkers, and superior speed and accuracy of analysis are the prime growth drivers of the MEA market. In addition, developing economies such as Saudi Arabia, South Africa and others will create new possibilities for this market. Nevertheless, higher capital expenditures, lack of reimbursement, and regulatory systems, and technical issues are the key restraints for the MEA cancer biomarkers market. Increase in the number of cancer cases as well as increasing research and development activities are expected to drive the growth of the cancer biomarkers market. Growing awareness regarding personalized medicine is anticipated to offer significant growth possibilities in the market in the coming years.
Biomarker research is increasing high importance these days due to its benefits such as accurate detection, easier diagnosis, and low chances of misdiagnosis during an early cancer diagnosis. Some of the key driving factors for the market in the Middle East and Africa are restructured drug delivery procedure, non-invasive technology, augmented rates of survival. Boost in government and private funding for oncology also fuels market development. The market is constrained by the high cost of diagnosis, issues linked to reimbursement and some of the regulatory policies prevalent within this region.
Top Oncology Research Center in Paris:
- Institut Curie
- American Hospital of Paris
- International Agency For Research on Cancer
- IRCAD France - Research Institute against Digestive
- Novartis Oncology
Top 10 Universities in Paris:
- Paris Science and Letters Research University
- Sciences Po Paris
- Sorbonne University
- École Polytechnique
- Université Paris Descartes
- Université Panthéon-Assas
- University Paris 1 Panthéon-Sorbonne
- Paris Diderot University
- École des Ponts ParisTech
- University Paris
